SOTIO Biotech Set to Showcase Innovations at Upcoming Meeting
SOTIO Biotech is a pioneer in the field of immuno-oncology, dedicated to enhancing patient outcomes through targeted cancer therapies. The company has announced its participation in the 2024 Society for Immunotherapy of Cancer Meeting scheduled for November. During this significant event, SOTIO will be presenting three poster sessions that offer exciting insights into their groundbreaking research.
Innovative Research Presentations
The posters presented by SOTIO will delve into various advanced methodologies aimed at boosting the efficacy of current cancer treatments. Notably, one of the research highlights will include exploring a revolutionary chimeric PGC-1? transgene designed to optimize CAR T cell efficacy in patients facing solid tumors. This study exemplifies SOTIO's commitment to scientific innovation and improving therapeutic outcomes for patients with challenging cancers.
VICTORIA-01 Study Insights
Among the ongoing projects is the VICTORIA-01 study, which is currently assessing the safety, tolerability, and initial effectiveness of SOT201. This innovative monotherapy is being tested for its role in treating advanced solid tumors. SOT201 itself is positioned as a next-generation PD-1-targeting immunocytokine, providing detailed data that could reshape treatment strategies in oncology.
Details of the Upcoming Posters
During the conference, SOTIO will present the following posters:
Title: “Chimeric PGC-1? expression in CAR-T cells improves metabolic function and anti-tumor efficacy in solid tumors”
Abstract Number: 273
Date: Thursday, November 7 and Friday, November 8, 2024
Presenting Author: Amy Jensen-Smith
Title: “VICTORIA-01: A multicenter, open-label, phase 1 study to evaluate the safety and preliminary efficacy of SOT201 in patients with advanced or metastatic solid tumors”
Abstract Number: 675
Date: Friday, November 8, 2024
Presenting Author: Aung Naing
Title: “SOT201, a novel cis-acting PD-1/IL-15 mutein-based immunocytokine that reinvigorates anti-tumor immunity qualitatively superior to PD-1/IL-2v-based IL-2/15R?? agonism”
Abstract Number: 940
Date: Saturday, November 9, 2024
Presenting Author: Irena Adkins
Future Access to Presentation Materials
For those interested in checking out the findings post-meeting, SOTIO plans to make all presentation materials available for further exploration. This initiative highlights the company's dedication to transparency and the dissemination of valuable scientific findings.
About SOTIO Biotech
SOTIO Biotech focuses on revolutionizing the treatment landscape for cancer through innovative research and development. The company is spearheading several clinical-stage projects, including SOT102, which targets Claudin-18.2, and BOXR1030, a cutting-edge CAR-T cell therapy aimed at GPC3-expressing tumors. With its focus on PD-1-targeting immunocytokine SOT201, SOTIO exemplifies a strong commitment to evolving patient-centric treatments in oncology. SOTIO is a proud member of the PPF Group and is at the forefront of integrating compelling scientific breakthroughs into meaningful therapeutic options for cancer patients.
Frequently Asked Questions
What is the significance of the SITC Annual Meeting for SOTIO?
The SITC Annual Meeting provides an important platform for SOTIO to share its latest research advancements in immunotherapy, highlighting its commitment to innovation in cancer treatment.
What are the key studies being presented by SOTIO?
SOTIO will present studies focusing on the efficacy of CAR T therapies and the novel immunocytokine SOT201, discussing their implications for treating advanced solid tumors.
How does SOTIO plan to share its findings post-presentation?
After the presentations, SOTIO intends to make the research materials accessible, allowing for broader understanding and discussion within the scientific community.
What innovative therapies are currently in SOTIO's pipeline?
In addition to SOT201, SOTIO’s pipeline includes SOT102 and BOXR1030, both of which are designed to tackle different aspects of cancer treatment with targeted approaches.
How is SOTIO connected to the PPF Group?
SOTIO operates under the umbrella of the PPF Group, which supports its mission and initiatives in advancing cancer therapies through substantial resources and collaborative opportunities.
